Curaleaf Completes Buyout of Remaining 45% Stake in Four 20 Pharma
May 1, 2026
Curaleaf Holdings completed the acquisition of the remaining 45% stake in Four 20 Pharma GmbH, a Germany-based medical cannabis producer and distributor. The deal makes Four 20 Pharma a fully integrated Curaleaf subsidiary and strengthens Curaleaf’s vertically integrated European supply chain from cultivation sources to licensed distribution in Germany.
- Buyers
- Curaleaf Holdings
- Targets
- Four 20 Pharma GmbH
- Industry
- Healthcare Services
- Location
- Germany
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.